Year: 2020
Language: English
Author(s): World Federation of Hemophilia
Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor therapies, FVIII-based immune tolerance induction (ITI) is still the only effective means to inhibitor eradication. With the recently introduced Atlanta protocol, emicizumab prophylaxis is given in combination with 50-100 IU/kg FVIII three times a week.
In this session from the WFH 2020 Virtual Summit, Alok Srivastava, Midori Shima, Gallia Levy & Steven Pipe explore the impact of emicizumab prophylaxis for non-inhibitor patients and examine the current status of clinical studies regarding emicizumab prophylaxis.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
This document is an introductory guide for people with hemophilia who wish to join the World Federation of Hemophilia (WFH)
The World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR) welcomes the participation of all Hemophilia Treatment Centres (HTCs) involved
This document is an introductory guide to the World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR). It answers basic
Follow the progress of hemophilia gene therapy clinicals with the WFH Gene Therapy for Hemophilia Pipeline tool to track clinical
In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the
In this session from the WFH 2020 Virtual Summit, Radoslaw Kaczmarek, Flora Peyvandi, Dan Hart & Johnny Mahlangu discuss novel